Literature DB >> 30319891

Near-infrared fluorescence lymphatic imaging in vascular endothelial growth factor-C overexpressing murine melanoma.

Sunkuk Kwon1, Fred Christian Velasquez1, Eva M Sevick-Muraca1.   

Abstract

In this study we employ a near-infrared fluorescence lymphatic imaging (NIRFLI) technique to longitudinally image spatial and temporal changes in the lymphatics in mice bearing vascular endothelial growth factor (VEGF)-C overexpressing B16F10 (VEGF-C-B16F10) or mock-transduced B16F10 (mock-B16F10) melanoma tumors. Our NIRFLI data show that ICG-laden lymph accumulates into a VEGF-C-B16F10 tumor compared to mock-B16F10 at 3 days post implantation, presumably due to increased lymphatic vessel permeability. Quantification shows a significantly greater percentage of ICG-perfused area in VEGF-C-B16F10 (7.6 ± 2) as compared to MOCK-B16F10 (1 ± 0.5; p = 0.02), which is also confirmed by quantification of the lymphatic leakage of evans blue dye (optical density at 610nm; VEGF-C-B16F10, 10.5 ± 2; mock-B16F10, 5.1 ± 0.5; p = 0.009); thereafter, lymphatic leakage is visualized only in the peritumoral region. Our imaging data also show that anti-VEGF-C treatment in VEGF-C-B16F10 restores normal lymphatic vessel integrity and reduces dye extravasation. Because NIRFLI technology can be used to non-invasively detect lymphatic changes associated with cancer, it may provide a new diagnostic to assess the lack of lymphatic vessel integrity that promotes lymphovascular invasion and to assess therapies that could arrest invasion through normalization of the lymphatic vasculature.

Entities:  

Year:  2018        PMID: 30319891      PMCID: PMC6179422          DOI: 10.1364/BOE.9.004631

Source DB:  PubMed          Journal:  Biomed Opt Express        ISSN: 2156-7085            Impact factor:   3.732


  16 in total

1.  Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications.

Authors:  Tohru Hoshida; Naohide Isaka; Jeroen Hagendoorn; Emmanuelle di Tomaso; Yen-Lin Chen; Bronislaw Pytowski; Dai Fukumura; Timothy P Padera; Rakesh K Jain
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

Review 2.  Inflammation-induced lymphangiogenesis and lymphatic dysfunction.

Authors:  Shan Liao; Pierre-Yves von der Weid
Journal:  Angiogenesis       Date:  2014-01-22       Impact factor: 9.596

3.  Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.

Authors:  Yulong He; Iiro Rajantie; Katri Pajusola; Michael Jeltsch; Tanja Holopainen; Seppo Yla-Herttuala; Thomas Harding; Karin Jooss; Takashi Takahashi; Kari Alitalo
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

4.  Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.

Authors:  Bronislaw Pytowski; Jeremy Goldman; Kris Persaud; Yan Wu; Larry Witte; Daniel J Hicklin; Mihaela Skobe; Kendrick C Boardman; Melody A Swartz
Journal:  J Natl Cancer Inst       Date:  2005-01-05       Impact factor: 13.506

5.  Lymphatic metastasis in the absence of functional intratumor lymphatics.

Authors:  Timothy P Padera; Ananth Kadambi; Emmanuelle di Tomaso; Carla Mouta Carreira; Edward B Brown; Yves Boucher; Noah C Choi; Douglas Mathisen; John Wain; Eugene J Mark; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2002-04-25       Impact factor: 47.728

6.  Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function.

Authors:  Naohide Isaka; Timothy P Padera; Jeroen Hagendoorn; Dai Fukumura; Rakesh K Jain
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

Review 7.  Emerging lymphatic imaging technologies for mouse and man.

Authors:  Eva M Sevick-Muraca; Sunkuk Kwon; John C Rasmussen
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

Review 8.  Lymphangiogenesis and cancer metastasis.

Authors:  Steven A Stacker; Marc G Achen; Lotta Jussila; Megan E Baldwin; Kari Alitalo
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

9.  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.

Authors:  V Joukov; K Pajusola; A Kaipainen; D Chilov; I Lahtinen; E Kukk; O Saksela; N Kalkkinen; K Alitalo
Journal:  EMBO J       Date:  1996-04-01       Impact factor: 11.598

Review 10.  The role of the VEGF-C/VEGFR-3 axis in cancer progression.

Authors:  J-L Su; C-J Yen; P-S Chen; S-E Chuang; C-C Hong; I-H Kuo; H-Y Chen; M-C Hung; M-L Kuo
Journal:  Br J Cancer       Date:  2006-12-12       Impact factor: 7.640

View more
  3 in total

Review 1.  The lymphatic vasculature: An active and dynamic player in cancer progression.

Authors:  Sara Rezzola; Elena C Sigmund; Cornelia Halin; Roberto Ronca
Journal:  Med Res Rev       Date:  2021-09-05       Impact factor: 12.388

2.  Lymph Leakage Promotes Immunosuppression by Enhancing Anti-Inflammatory Macrophage Polarization.

Authors:  Andrés A Herrada; Alexandra Olate-Briones; Rodrigo Lazo-Amador; Chaohong Liu; Bairon Hernández-Rojas; Gonzalo Riadi; Noelia Escobedo
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

Review 3.  Intrathecal drug delivery in the era of nanomedicine.

Authors:  M J Fowler; J D Cotter; B E Knight; E M Sevick-Muraca; D I Sandberg; R W Sirianni
Journal:  Adv Drug Deliv Rev       Date:  2020-03-03       Impact factor: 15.470

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.